Spondyloarthritis & psoriatic arthritis
Long‐Term Follow‐Up of Anti‐Infliximab Antibodies in Patients With Radiographic Axial Spondyloarthritis: A Marker of Drug Survival and Tapering
Authors' conclusion
This study provided novel data that anti-IFX antibodies is a parameter for reduced tapering survival
Study context
- Population
- Patients with r-axSpA who received IFX
- Participants
- 60 patients
- Exposure
- Anti-IFX antibody positive vs anti-IFX antibody negative
- Anti-IFX positiven = 27
- Outcome
- Tapering survival
Methodological detailsevaluated retrospectively
- Evaluated retrospectively
Main finding
As reported in the abstract
P = 0.004
Observational data: associations, not effects.
Further findings
Concomitant MTX use
P = 0.048
Clinical response to second TNFi after IFX failure · 3 months
P = 0.005
Clinical response to second TNFi after IFX failure · 6 months
P = 0.017
- Treatment failures · 48 to 54 weeks · more treatment failures
- P = 0.028
- Overall IFX survival · reduced
- P < 0.001
- Sustained responses · lower
- P = 0.044
Anti-IFX antibodies detected
- Anti-IFX antibodies detected
- 27 (45%)
- Positive in first year of IFX
- 23 (85.1%)
Safety
| Outcome | P value |
|---|---|
| Infusion reactions · 22 to 24 weeksMore infusion reactions | P = 0.020 |
| Infusion reactions · 48 to 54 weeksMore infusion reactions | P = 0.034 |
Original publication
Long‐Term Follow‐Up of Anti‐Infliximab Antibodies in Patients With Radiographic Axial Spondyloarthritis: A Marker of Drug Survival and Tapering. Arthritis Rheumatol. Published 14 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →